Applies to most patients with one or two positive sentinel lymph nodes ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

For years, surgery for patients with stage III melanoma -- melanoma that has spread to the lymph nodes -- involved removing those lymph nodes along with the primary tumor. Known as completion lymph ...

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

Gastric cancer remains one of the leading causes of cancer-related death worldwide, and surgical resection with lymphadenectomy is the only potentially curative option. Lymphadenectomy—the systematic ...

Future breast cancer treatment options may not only increase patients’ survival but also reduce or eliminate their need for surgery altogether, says breast cancer surgeon Sara Javid, MD, Fred ...

Thousands of women could now be spared one of the most debilitating side-effects of breast cancer treatment - lifelong ...